Volume | 1,979,052 |
|
|||||
News | (1) | ||||||
Day High | 2.115 | Low High |
|||||
Day Low | 1.92 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.93 | 1.92 | 2.115 | 1.91 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,425 | 1,979,052 | $ 2.05 | $ 4,056,978 | - | 0.70 - 3.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:48:51 | 100 | $ 2.075 | USD |
Esperion Therapeutics (ESPR) Options Flow Summary
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
373.81M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.91 | 2.115 | 1.71 | 1.90 | 5,611,406 | 0.165 | 8.64% |
1 Month | 2.60 | 3.40 | 1.71 | 2.62 | 8,957,761 | -0.525 | -20.19% |
3 Months | 2.19 | 3.40 | 1.71 | 2.51 | 6,428,140 | -0.115 | -5.25% |
6 Months | 0.82 | 3.40 | 0.706 | 2.24 | 5,955,023 | 1.26 | 153.05% |
1 Year | 1.30 | 3.40 | 0.70 | 1.92 | 4,564,578 | 0.775 | 59.62% |
3 Years | 28.63 | 28.78 | 0.70 | 3.83 | 2,631,691 | -26.56 | -92.75% |
5 Years | 42.09 | 79.989 | 0.70 | 8.80 | 1,819,028 | -40.02 | -95.07% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |